

Step Therapy Approval Criteria

Effective Date: 07/01/2019

This document contains Step Therapy Approval Criteria for the following medications:

- 1. Colcrys (colchicine)
- 2. Dovonex (calcipotriene)
- 3. Enbrel (etanercept)
- 4. Humira (adalimumab)
- 5. Imitrex Injection vial and STATdose (sumatriptan succinate)
- 6. Invokana (canagliflozin)
- 7. Jardiance (empagliflozin)
- 8. Levitra (vardenafil)
- 9. Lyrica (pregabalin)
- 10. Nexium (esomeprazole)
- 11. Onfi (clobazam)
- 12. OxyContin (oxycodone extended-release)
- 13. Protopic (tacrolimus)
- 14. Risperdal Consta (risperidone long-acting injection)
- 15. Soriatane (acitretin)
- 16. Symbicort (budesonide/formoterol)
- 17. Victoza (liraglutide)



- 18. Vyvanse (lisdexamfetamine)
- 19. Xifaxan (rifaximin)



Step Therapy Approval Criteria Colcrys (colchicine)

Generic name: colchicine **Brand name:** Colcrys

Medication class: Antigout; antiinflammatory

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

- Previous failure of one of the following in the past 365 days:
 - o A formulary NSAID
 - o A formulary glucocorticoid
 - o Allopurinol
 - o Probenecid/colchicine

Additional considerations:

• Quantity Limit (QL) of 60 tablets per 30 days

Formulary Management Review: Initial: October 2016



Step Therapy Approval Criteria Dovonex (calcipotriene)

Generic name: calcipotriene **Brand name:** Dovonex

Medication class: Antipsoriatic, Synthetic Vitamin D3

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of a formulary topical corticosteroid in the past 365 days

Formulary Management Review: Initial: January 2016



Step Therapy Approval Criteria Enbrel (etanercept)

Generic name: etanercept **Brand name:** Enbrel

Medication class: TNF inhibitor; immune suppressant

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

- Previous failure of one of the following in the past 365 days:
 - o Asacol
 - o Balsalazide
 - o Dipentum
 - o Methotrexate
 - o Rowasa
 - o Azathioprine
 - o Cyclosporine
 - o Hydroxychloroquine
 - o Hydroxyurea
 - o Leflunomide
 - o Mercaptopurine
 - o Soriatane
 - o Sulfasalazine

Additional considerations:

• Quantity limit (QL) of 4 injections per 28 days

Formulary Management Review:

Initial: 10/01/2013

Revision: 04/01/2015, 10/01/2016



Step Therapy Approval Criteria Humira (adalimumab)

Generic name: adalimumab

Brand name: Humira

Medication class: TNF inhibitor; monoclonal antibody; antirheumatic

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

- Previous failure of one of the following in the past 365 days:
 - o Asacol
 - o Balsalazide
 - o Dipentum
 - o Methotrexate
 - o Rowasa
 - o Azathioprine
 - o Cyclosporine
 - o Hydroxychloroquine
 - o Hydroxyurea
 - o Leflunomide
 - o Mercaptopurine
 - o Soriatane
 - Sulfasalazine

Additional considerations:

• Quantity limit (QL) of 4 injections per 28 days

Formulary Management Review:

Initial: 10/01/2013

Revision: 04/01/2015, 10/01/2016



Step Therapy Approval Criteria Imitrex Injection vial and STATdose (sumatriptan succinate)

Generic name: sumatriptan

Brand name: Imitrex Injection vial and Imitrex STATdose

Medication class: 5HT-1 serotonin receptor agonist; antimigraine

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of sumatriptan oral tablets or sumatriptan nasal spray in the past 365 days

Additional considerations:

• Quantity limit (QL) of 6 doses (3 ml) per 30 days

Formulary Management Review: Initial: 10/01/2013



Step Therapy Approval Criteria Invokana (canagliflozin)

Generic name: canagliflozin **Brand name:** Invokana

Medication class: SGLT2 inhibitor

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of a formulary diabetes medication in the past 365 days.

Formulary Management Review: Initial: July 2019 Revision:



Step Therapy Approval Criteria Jardiance (empagliflozin)

Generic name: empagliflozin **Brand name:** Jardiance

Medication class: SGLT2 inhibitor

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of a formulary diabetes medication in the past 365 days.

Formulary Management Review: Initial: July 2017



Step Therapy Approval Criteria Levitra (vardenafil)

Generic name: vardenafil **Brand names:** Levitra

Medication class: Phosphodiesterase-5 (PDE-5) inhibitor

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of sildenafil citrate (generic for Viagra) in the past 365 days

Additional considerations:

• Quantity Limit (QL) of 6 tablets per 30 days

Formulary Management Review:

Initial: July 2018 Revision:



Step Therapy Approval Criteria Lyrica (pregabalin)

Generic name: pregabalin **Brand name:** Lyrica

Medication class: GABA analog; anticonvulsant

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of gabapentin or duloxetine in the past 365 days

Formulary Management Review: Initial: January 2019



Step Therapy Approval Criteria Nexium (esomeprazole)

Generic name: esomeprazole

Brand name: Nexium

Medication class: Proton pump inhibitor

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of omeprazole or pantoprazole in the past 365 days

Additional considerations:

• Quantity Limit (QL) of 30 capsules per 30 days

Formulary Management Review:

Initial: 01/01/2015

Revision: 04/01/2015, 04/01/2018



Step Therapy Approval Criteria Onfi (clobazam)

Generic name: clobazam

Brand name: Onfi

Medication class: Anticonvulsant

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of lamotrigine in the past 365 days

Step 2:

• Previous failure of topiramate in the past 365 days

Formulary Management Review: Initial: July 2019



Step Therapy Approval Criteria OxyContin (oxycodone extended-release)

Generic name: oxycodone extended-release

Brand name: OxyContin

Medication class: Opioid analgesic

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of one formulary long-acting opioid analgesic (i.e. morphine sulfate extended-release, fentanyl patches or methadone) in the past 365 days.

Formulary Management Review: Initial: January 2018 Revision:

Page 1 of 1



Step Therapy Approval Criteria Protopic (tacrolimus)

Generic name: tacrolimus **Brand names:** Protopic

Medication class: Calcineurin inhibitor

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of one formulary topical corticosteroid in the past 365 days

Additional considerations:

• Quantity Limit (QL) of 100 grams per 30 days

Formulary Management Review:

Initial: April 2017



Step Therapy Approval Criteria Risperdal Consta (risperidone long-acting injectable)

Generic name: risperidone long-acting injectable

Brand name: Risperdal Consta

Medication class: Atypical antipsychotic

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of risperidone tablets in the past 365 days.

Formulary Management Review: Initial: July 2017



Step Therapy Approval Criteria Soriatane (acitretin)

Generic name: acitretin
Brand name: Soriatane
Medication class: Retinoid

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of methotrexate in the past 365 days.

Formulary Management Review: Initial: October 2016



Step Therapy Approval Criteria Symbicort (budesonide/formoterol)

Generic name: budesonide/formoterol

Brand name: Symbicort

Medication class: Inhaled glucocorticoid/long-acting beta-agonist

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of fluticasone/salmeterol (generic Advair Diskus) or Advair HFA in the past 365 days.





Step Therapy Approval Criteria Victoza (liraglutide)

Generic name: liraglutide **Brand name:** Victoza

Medication class: GLP-1 receptor agonist

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of a formulary diabetes medication in the past 365 days.

Formulary Management Review: Initial: January 2018



Step Therapy Approval Criteria Vyvanse (lisdexamfetamine)

Generic name: lisdexamfetamine

Brand name: Vyvanse

Medication class: CNS stimulant

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

 Previous failure of a formulary generic amphetamine product in the past 365 days

Step 2:

• Previous failure of formulary generic methylphenidate product in the past 365 days

Additional considerations:

• Quantity Limit (QL) of 30 capsules per 30 days

Formulary Management Review:

Initial: April 2017



Step Therapy Approval Criteria Xifaxan (rifaximin)

Generic name: rifaximin
Brand name: Xifaxan
Medication class: Rifamycin

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

 Previous failure of lactulose, dicyclomine, ciprofloxacin or azithromycin in the past 180 days

Additional considerations:

- Quantity limit (QL) of 60 tablets per 30 days for the 550 mg tablets
- Quantity limit (QL) of 180 tablets per 30 days for the 200 mg tablets

Formulary Management Review:

Initial: 07/01/2015 Revision: October 2017